Marty Felsenthal

Marty is a venture capital and growth stage investor who has worked exclusively with innovative, disruptive, and rapidly growing healthcare software and services companies over the last 25 years.

Marty is a partner at Health Velocity Capital, which invests in healthcare software and services businesses with a mission of partnering with entrepreneurs to help create a more affordable, sustainable, consumer-friendly healthcare system. In his own words, “I am excited to play a strategic, supporting role in fueling Compass’ continued growth as it enters new markets and collaborates with other providers to drive value while continuing to redefine the care experience for its patients and providers.”

Spanning three decades, Marty has consistently helped finance and build companies that created new healthcare sectors within healthcare and that became market leaders. He has served on the Boards of Directors of innovative companies such as TelaDoc (NYSE: TDOC); Titan Health (acquired by United Surgical Partners); US Renal Care; NovoLogix (acquired by CVS Health); MDLive (acquired by Cigna); OnShift (acquired by ShiftKey); IVX Health; and Well Health.
Over the course of his career, he has invested on behalf of financial limited partners as well as in partnership with some of the nation's largest and most influential healthcare payers, health systems, pharmacy chains, and healthcare foundations. Marty also serves as an adviser to the California Healthcare Foundation Innovation Fund.